Lloyd George W.'s Form 4 filing
Royalty Pharma plc (RPRX) · filed Jul 27, 2021
- Accession no.
- 0001209191-21-048317
- Filed
- Jul 27, 2021
- Trade date
- Jul 26, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $531.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lloyd George W.CIK 0001814899 | Officer (EVP, Investments & GC) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 to $40.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.56 to $40.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
All reported transactions were effected pursuant to 10b5-1 plans adopted by the reporting person on December 28, 2020.